Blog

Genentech Still Holding Out

Genentech (DNA, $96.00, up $1.35) continued higher throughout the week as it awaits word from a “special committee” that is evaluating the $44 billion bid to buy the company. Swiss pharmaceutical giant Roche is on the other end of that bid and is also waiting for an answer to itsRead more

More

NewsFlash: Chipotle Under $70

Chipotle Mexican Grill (CMG, $69.01, down $14.79) has dipped below $70 again after opening the trading session at $74.29. The stock traded to a high of $75.50 but the bears have been firmly in control since the opening bell. I mentioned the after-hours trading was a good indication that theRead more

More

Wachovia Continues Higher

Wachovia (WB, $17.65, up $0.86) was up another 5% yesterday following Tuesday’s massive 29% gain despite an earnings report that I still find hard to fathom. The stock hit a low of $11.65 right after Tuesday’s anouncement of a $9 billion loss, rebounded that same day, and hit a highRead more

More

Chipotle Misses, Stock Drops in After-Hours

Chipotle Mexican Grill (CMG, $83.80, up $2.14) missed earnings by a penny and it paid for in after-hours trading last night. The stock was down $9, or 10%, to $75. Other than missing by a penny, it was an earnings report that deserved an A+. For 2Q, Chipotle reported anRead more

More

Chipotle Mexican Grill On Deck

Chipotle Mexican Grill (CMG, $82.50, up $0.84) will announce earnings after the market closes today and it will be interesting to see how the company is holding up. A slowing economy, higher menu prices and a salmonella scare could factor into where this stock opens on Thursday. We have hadRead more

More

Merck Update

It’s been a rough couple of days for Merck (MRK, $31.33, down $4.00). The stock followed Monday’s 6% decline with a 11% drop on Tuesday after lackluster earnings and some damaging information for the company’s cholesterol drug Vytorin. On Monday when Merck was at $36, I mentioned that earnings wereRead more

More

Yahoo Holds up in After-Hours

Yahoo (YHOO, $21.40, down $0.27) announced earnings after the closing bell yesterday and in after-hours trading the stock held up well. For Q2, the company reported earnings of $131 million, or $0.09 a share. This was a drop from $161 million, or $0.11 a share, in the year-earlier quarter. WallRead more

More

Apple Beats, Outlook Disappoints

You can always expect an extreme move in Apple’s (AAPL, $152.52, down $13.77) stock the day after an earnings announcement. Another thing you can expect is for Apple to beat Wall Street’s expectations — they have for eight straight quarters — and yesterday was no different. The company reported earningsRead more

More

Lottery Plays Stopped Out

The Financial stocks continued their rally in the morning session on Monday but faded by the time the closing bell sounded. Some of the positions went on to double in price and that is really when they should have been sold, regardless of a stop. Sometimes you have to workRead more

More

Genentech Next?

Genentech (DNA, $93.88, up $12.06) rallied 15% on news that Swiss pharmaceutical giant Roche announced a $44 billion bid to buy the remaining 45% of the company that it does not own. The offer is for $89.00 a share but the market is clearly pricing in a higher bid. Here’sRead more

More

CFTC Disclosure:

GOVERNMENT REGULATIONS REQUIRE DISCLOSURE OF THE FACT THAT WHILE THESE METHODS MAY HAVE WORKED IN THE PAST, PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE PERFORMANCE. WHILE THERE IS A POTENTIAL FOR PROFITS THERE IS ALSO A RISK OF LOSS. A LOSS INCURRED IN CONNECTION WITH Momentum Options Trading, LLC CAN BE SIGNIFICANT. YOU SHOULD THEREFORE CAREFULLY CONSIDER WHETHER TRADING IS SUITABLE FOR YOU IN LIGHT OF YOUR FINANCIAL CIRCUMSTANCE. THERE IS SUBSTANTIAL RISK IN TRADING. A LOSS INCURRED IN CONNECTION WITH FUTURES TRADING CAN BE SIGNIFICANT. WE MAKE NO CLAIM REGARDING PAST OR FUTURE PERFORMANCE. WE MERELY TRACK EVERY TRADE AND SHOW THE PERFORMANCE OF ALL TRADES THE SYSTEM OR NEWSLETTER PRODUCES. SIMULATED TRADING IS DIFFERENT THAN TRADING REAL MONEY. HYPOTHETICAL RESULTS ARE NOT REAL RESULTS. PLEASE CONTACT YOUR BROKER ABOUT THE RISK OR TRADING STOCKS, OPTIONS OR FUTURES. ALL COMMUNICATIONS ARE OPINIONS NOT ADVICE.

CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.